Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Patients with immune-mediated inflammatory diseases (IMIDs) and acquired and genetic immunodeficiencies receiving therapeutic infusions are considered high risk for SARS-CoV-2 infection. However, the seroprevalance in this group and the safety of routine administrations at outpatient infusion centers are unknown. To determine the infection rate and clinical-social factors related to SARS-CoV-2 in asymptomatic patients with IMIDs and immunodeficiencies receiving routine non-cancer therapeutic infusions, we conducted a seroprevalence study at our outpatient infusion center. We report the first prospective SARS-CoV-2 sero-surveillance of 444 IBD/IMID, immunodeficiency, and immune competent patients at an outpatient infusion center in the U.S. showing lower seroprevalence in patients compared with the general population and provide clinical and social characteristics associated with seroprevalence in this group. These data suggest that patients can safely continue infusions at outpatient centers.
Article activity feed
-
SciScore for 10.1101/2021.03.15.21253615: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: 4,5 The Icahn School of Medicine at Mount Sinai Institutional Review Board approved the study. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A limitation of the study is that it is from a single center. In conclusion, our data suggest patients can safely continue routine infusions …
SciScore for 10.1101/2021.03.15.21253615: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: 4,5 The Icahn School of Medicine at Mount Sinai Institutional Review Board approved the study. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A limitation of the study is that it is from a single center. In conclusion, our data suggest patients can safely continue routine infusions at outpatient centers during the COVID-19 pandemic as the seroprevalence at our center was low; longitudinal follow-up of these patients would confirm this point. This information is useful to practitioners as many patients have opted to delay or discontinue infusions during the pandemic, risking disease flares and complications thereof, or switched to home infusions, which has been associated with adverse outcomes.2,3 This is all the more important in our urban cohort given the disparity of seroprevalence by socio-economic factors. Finally, the functionality and durability of immune responses to SARS-CoV-2 infection, as well as COVID-19 vaccines, remain to be determined in IBD patients, who were not included in COVID-19 vaccine trials.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-